Accredited Investors Inc. Boosts Stake in Eli Lilly and Company (LLY)

Accredited Investors Inc. grew its holdings in Eli Lilly and Company (NYSE:LLY) by 0.4% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,259 shares of the company’s stock after acquiring an additional 14 shares during the quarter. Accredited Investors Inc.’s holdings in Eli Lilly and were worth $268,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Vanguard Group Inc. raised its stake in shares of Eli Lilly and by 3.3% in the first quarter. Vanguard Group Inc. now owns 68,597,006 shares of the company’s stock valued at $5,769,694,000 after purchasing an additional 2,181,701 shares in the last quarter. BlackRock Inc. raised its stake in shares of Eli Lilly and by 2,628.5% in the first quarter. BlackRock Inc. now owns 62,260,488 shares of the company’s stock valued at $5,236,731,000 after purchasing an additional 59,978,664 shares in the last quarter. State Street Corp raised its stake in shares of Eli Lilly and by 1.6% in the first quarter. State Street Corp now owns 42,363,935 shares of the company’s stock valued at $3,563,230,000 after purchasing an additional 651,424 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Eli Lilly and by 8.4% in the first quarter. Geode Capital Management LLC now owns 9,103,975 shares of the company’s stock valued at $764,597,000 after purchasing an additional 708,597 shares in the last quarter. Finally, Janus Capital Management LLC raised its stake in shares of Eli Lilly and by 2.8% in the first quarter. Janus Capital Management LLC now owns 8,723,692 shares of the company’s stock valued at $733,731,000 after purchasing an additional 237,619 shares in the last quarter. 75.72% of the stock is owned by institutional investors.

In other news, major shareholder Lilly Endowment Inc sold 205,000 shares of the business’s stock in a transaction on Wednesday, October 4th. The stock was sold at an average price of $86.81, for a total transaction of $17,796,050.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Over the last quarter, insiders have sold 990,000 shares of company stock valued at $82,949,650. Corporate insiders own 0.20% of the company’s stock.

LLY has been the subject of a number of recent research reports. Piper Jaffray Companies restated a “buy” rating and issued a $103.00 target price on shares of Eli Lilly and in a research note on Thursday, August 31st. Zacks Investment Research upgraded Eli Lilly and from a “hold” rating to a “buy” rating and set a $94.00 target price for the company in a research note on Monday, July 17th. Jefferies Group LLC restated a “buy” rating and issued a $89.00 target price (down from $94.00) on shares of Eli Lilly and in a research note on Thursday, August 24th. Cowen and Company restated a “buy” rating and issued a $95.00 target price on shares of Eli Lilly and in a research note on Wednesday, October 4th. Finally, Berenberg Bank restated a “buy” rating and issued a $100.00 target price on shares of Eli Lilly and in a research note on Thursday, July 27th. Three equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and twelve have issued a buy rating to the stock. Eli Lilly and has a consensus rating of “Hold” and an average target price of $88.42.

WARNING: This piece was originally reported by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of international copyright & trademark legislation. The legal version of this piece can be viewed at https://transcriptdaily.com/2017/10/09/accredited-investors-inc-boosts-stake-in-eli-lilly-and-company-lly.html.

Eli Lilly and Company (NYSE LLY) opened at 87.08 on Monday. The firm has a market capitalization of $91.87 billion, a price-to-earnings ratio of 37.68 and a beta of 0.34. Eli Lilly and Company has a 1-year low of $64.18 and a 1-year high of $89.09. The firm’s 50-day moving average price is $82.21 and its 200 day moving average price is $82.15.

Eli Lilly and (NYSE:LLY) last released its earnings results on Tuesday, July 25th. The company reported $1.11 earnings per share for the quarter, beating analysts’ consensus estimates of $1.05 by $0.06. The firm had revenue of $5.82 billion during the quarter, compared to the consensus estimate of $5.60 billion. Eli Lilly and had a return on equity of 28.71% and a net margin of 11.12%. The company’s revenue was up 7.8% compared to the same quarter last year. During the same period in the prior year, the company posted $0.86 EPS. On average, analysts predict that Eli Lilly and Company will post $4.16 EPS for the current year.

Eli Lilly and Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply